News

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...
The new weight-loss option will cut what ... year at current prices if every adult dealing with obesity took the drugs. Competition that drives down the cost of Wegovy and Zepbound could help ...
The announcement coincides with a federal deadline on May 22, for manufacturers to cease distributing less expensive, compounded versions of the drug. Novo Nordisk officials said the one-time ...
The announcement coincides with ... In February, Eli Lilly cut the monthly price for lower-dosage vials of its obesity drug Zepbound by $50 for consumers who pay cash via the drugmaker's ...
Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA asset tirzepatide, respectively sold under the brand names Zepbound and ...
Its share price fell by a further 3 per cent on the Copenhagen stock exchange following the announcement ... its lead in the weight-loss market to Zepbound, an injection manufactured by rival ...
As a result, Zepbound will be dropped from preferred coverage on CVS’s core formulary in favor of Novo's drug. The consensus indicates Lilly’s share price plunge was directly tied to CVS’s ...
Until this announcement ... price follow a similar move by Lilly. Last month, LLY also announced that it is reducing the prices of 7.5 mg and 10 mg single-dose vials of obesity treatment ...
Novo Nordisk’s shares rose by 3.8% in US markets following the announcement ... Zepbound and Novo Nordisk’s Wegovy cost over $1,300 per month before insurance and other rebates at retail prices.
The lower price is available to both uninsured patients and people whose insurance does not cover weight-loss drugs, the company also said. Last week, Eli Lilly, the maker of Zepbound, also cut ...